An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Krystal Biotech, a commercial-stage biotechnology company, will report its first quarter 2024 financial results on May 6, 2024. The Company's management will host a conference call and webcast to discuss the results and provide a business update.
Krystal Biotech, un'azienda biotecnologica in fase commerciale, comunicherà i risultati finanziari del primo trimestre del 2024 il 6 maggio 2024. La direzione dell'azienda terrà una conferenza telefonica e un webcast per discutere i risultati e fornire un aggiornamento sullo stato dell'azienda.
Krystal Biotech, una empresa de biotecnología en etapa comercial, reportará los resultados financieros del primer trimestre de 2024 el 6 de mayo de 2024. La dirección de la empresa organizará una llamada de conferencia y una transmisión en web para discutir los resultados y ofrecer una actualización sobre el negocio.
상업 단계의 생명공학 회사인 크리스탈 바이오텍은 2024년 5월 6일에 2024년도 1/4분기 재무 결과를 보고할 예정입니다. 회사 경영진은 결과를 논의하고 사업 업데이트를 제공하기 위해 전화 회의와 웹캐스트를 주최할 것입니다.
Krystal Biotech, une entreprise de biotechnologie en phase commerciale, annoncera ses résultats financiers pour le premier trimestre 2024 le 6 mai 2024. La direction de l'entreprise organisera une conférence téléphonique et une webdiffusion pour discuter des résultats et fournir une mise à jour sur les affaires.
Krystal Biotech, ein Unternehmen der Biotechnologiebranche in der kommerziellen Phase, wird am 6. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Management des Unternehmens wird einen Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Positive
None.
Negative
None.
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update.
For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
